Review

The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy

Ning Guoa,1, Ji-Bin Liub,1, Wen Lia,⇑,1, Yu-Shui Mab,c,⇑,1, Da Fud,a

a National Engineering Laboratory for Deep Process of Rice and Byproducts, College of Food Science and Engineering, Central South University of Forestry and Technology, Changsha 410004, Hunan, China
b Institute of Oncology, Affiliated Tumor Hospital of Nantong University, Nantong 226631, China
c Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China
d General Surgery, Ruijin Hospital & Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Due to its high accuracy and efficiency, CRISPR/Cas9 techniques may provide a great chance to treat some gene-related diseases. Researchers used the CRISPR/Cas9 technique to cure or alleviate cancers through different approaches, such as gene therapy and immune therapy. The treatment of ocular diseases by Cas9 has entered into clinical phases.

HIGHLIGHTS

- Due to its high accuracy and efficiency, CRISPR/Cas9 techniques may provide a great chance to treat some gene-related diseases.
- Researchers used the CRISPR/Cas9 technique to cure or alleviate cancers through different approaches, such as gene therapy and immune therapy.
- The treatment of ocular diseases by Cas9 has entered into clinical phases.

ABSTRACT

Background: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is derived from the bacterial innate immune system and engineered as a robust gene-editing tool. Due to the higher specificity and efficiency of CRISPR/Cas9, it has been widely applied to many genetic and non-genetic disease, including cancers, genetic hemolytic diseases, acquired immunodeficiency syndrome, cardiovascular diseases, ocular diseases, and neurodegenerative diseases, and some X-linked diseases. Furthermore, in terms of the therapeutic strategy of cancers, many researchers used the CRISPR/Cas9 technique to cure or alleviate cancers through different approaches, such as gene therapy and immune therapy.

Aim of Review: Here, we conclude the recent application and clinical trials of CRISPR/Cas9 in non-cancerous diseases and cancers and pointed out some of the problems to be solved.

Key Scientific Concepts of Review: CRISPR/Cas9, derived from the microbial innate immune system, is developed as a robust gene-editing tool and has been applied widely. Due to its high accuracy and efficiency, CRISPR/Cas9 techniques may provide a great chance to treat some gene-related diseases by disrupting, inserting, correcting, replacing, or blocking genes for clinical application with gene therapy.

© 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

History of CRISPR

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) was first discovered in Escherichia coli and described as a 1,664-nucleotide sequence by Ishino and his colleagues in 1987 [1] (Fig. 1). Six years later, Mojica and Van Soolingen found similar DNA fragments in Haloarcula and Haloferax archaea[2], and M. tuberculosis[3] separately. By 2000, Mojica’s group had identified...
CRISPR DNA sequences in twenty microbial species[4]. Following the development of DNA sequencing techniques, the broader existence of CRISPR was reported in 2005: the majority of archaea (90%) and certain bacteria (40%) contain CRISPR fragments[5].

However, compared with its wide discovery in the first two decades, the functions of the CRISPR still kept unknown until 2007. Before making clear its functions, two crucial research speeded up the development: the study of genes adjacent to the CRISPR locus in 2002[6], and the discovery of foreign viral DNA in CRISPR spacers in 2005[5,7,8], which directly propelled the proposing of the hypothesis that the CRISPR system is an innate immune system in archaea and bacteria to fight against viruses[5,7,8]. Finally, in 2007, the hypothesis was verified by experiments in Barrangou’s lab, and the functions of the ‘weird’ CRISPR sequences were finally figured out[9].

Due to the excellent ability to target and cleave specific DNA sequences, CRISPR was engineered as a gene-editing tool in 2012[10-13]. Compared with the previous gene-editing tools, including zinc finger nuclease (ZFN) and transcription activator-like effector nuclease (TALENs), the CRISPR-based gene-editing tool performs dramatically better. More importantly, CRISPR is easier to design for researchers, which accelerates its application widely. At present, CRISPR/Cas9 has been a routine and versatile method to edit genes over all the world. The first clinical application occurred in 2016. Chinese group injected CRISPR/Cas9-edited cells to treat aggressive lung cancer at the West China Hospital[14]. In recent years, a lot of clinical trials have been processing and some results have been reported, including the CRISPR/Cas9-based clinical treatment of acquired immunodeficiency syndrome (AIDS)[15], sickle cell disease (SCD)[16], β-thalassemia[16], and various cancers[17,18].

In recognition of their contribution to developing CRISPR/Cas9 genome editing techniques, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in 2020.

**Classification of CRISPR**

The classification of CRISPR is updated continually. In 2015, only five types and 18 subtypes were recognized[19], while it had expanded to six types and 33 subtypes after five years[20]. According to the number of Cas proteins, CRISPR is generally divided into two classes: CRISPR/Cas system contains multiple Cas proteins in class 1 system, and only has a single Cas protein in class 2 system[21]. The type and subtype of CRISPR are based on different signature proteins. For example, Cas9 protein only exists in the type II CRISPR system, and Cas2 is the signature protein of subtype II-A. The class 1 CRISPR includes types I, III, and IV, whereas type II, V and VI belong to class 2 CRISPR[20]. More information about CRISPR classification has been concluded by Makarova[20].

**Biosynthesis of CRISPR/Cas9**

CRISPR/Cas9, the type II CRISPR system of class 2[20], is one of the most well-known CRISPR systems (Fig. 2). Gene-editing tool based on CRISPR/Cas9 is considered an efficient and reliable method to edit genes, and it is applied most widely among all CRISPR systems at present[21]. Intracellularly, genomic CRISPR/Cas9 locus comprises trans-activating CRISPR RNA (tracrRNA) gene, Cas9 gene, CRISPR repeat and spacer sequences, and their transcriptional products are tracrRNA, Cas9 protein, and Pre-crRNA separately[22]. After tracrRNA is anchored on the Cas9 enzyme, the dissociative part of tracrRNA is paired with the repeat sequences of Pre-crRNA to form Cas9 precursors. Finally, mature Cas9 complexes are formed by clipping Pre-crRNA under the catalysis of RBase III[23].

Cas9 complexes in microbes could detect foreign DNA fragments complementary to spacer sequences then create double-strand breaks (DSBs) in the specific points, which provides innate protection against viral genomes. Based on its mechanism, Jinek’s lab simplified and microbial CRISPR/Cas9 by fusing duo-tracrRNA:crRNA units as a single, truncated RNA chimeras, and they utilized the engineered CRISPR/Cas9 to introduced DSBs successfully[10]. The simplified CRISPR/Cas9 only contains a single but bifunctional Cas9 protein[24] and a single small guide RNA (sgRNA) to catalyze both DNA targeting and cleaving processes, which promoted its wide use (Fig. 3A). Compared with the previous generation of gene-editing tools, including ZFN and TALENs, CRISPR/Cas9 is more specific but less cytotoxic[25,26]. It is also simpler to design for researchers, which speeds its applications up dramatically.

**Mechanism of CRISPR/Cas9-mediated gene editing**

Mechanically, CRISPR/Cas9 is quite different from the previous generation gene-editing tools. The previous tools, including ZFN
and TALENs, are based on the pairing between protein domains and nucleotides. ZFN relies on multiple Cys2-His2 zinc-finger proteins to target specific NDA sequences. Each zinc-finger protein consists of about 30 amino acids and is capable of pairing three nucleotides. After designing and assembling different zinc-finger domains, ZFN can recognize the DNA sequences that contain 9–18 specific nucleotides[27]. The recognition domains of TALENs are derived from Xanthomonas, called transcription activator-like effector (TALE). Single TALE repeats are composed of 33–35 amino acids and recognize one nucleotide according to the 12th and 13th amino acids of TALE[28]. Both ZFN and TALENs exert cleavage functions by Fok I nuclease that is activated in dimers. Therefore, ZFN and TALENs need a pair respectively when editing genes, which increases the threshold and is inconvenient to design for researchers[27,28].

CRISPR/Cas9 targets the specific DNA sequences via complementary base pairing. Engineered CRISPR/Cas9 gene-editing tools (abbreviated as CRISPR/Cas9 without specific explanation) consist of Cas9 nuclease and sgRNA (Fig. 3B). After binding between the Cas9-anchor sequence (tracrRNA or “scaffold” sequence) of sgRNA and the recognition lobe (REC) of Cas9, the user-defined 20 nucleotide targeting sequence (also called “spacer” sequence) in sgRNA targets the specific DNA site, then the Cas9 nuclease lobe (NUC) exert cleavage to generate DSB [29]. Intracellularly, DSBs are mainly repaired by two pathways: 1. non-homologous end-joining (NHEJ)[30], a pathway introduces random indels, leading to gene knocking out, and 2. homology-directed repair (HDR)[31], a pathway that needs homologic template sequences, resulting in gene correcting, knocking in or replacement. Noticeably, Protospacer Adjacent Motif (PAM), the first three bases in the spacer sequence, is essentially for gene targeting. CRISPR/Cas9 firstly binds with potential DNA fragments containing PAM sites. Then, the whole spacer sequence pairs the remanent nucleotides[32].

**The further development of CRISPR/Cas9 technology**

Following the rapid development and the considerable success of the CRISPR/Cas9 technique, CRISPR/Cas9 is re-engineered to apply in other aspects. For example, utilizing the targeting ability of CRISPR/Cas9, the CRISPR interference(CRISPRi) and catalytically-dead Cas9 enzyme (dCas9) were designed by removing nuclease domains to decrease or suppress gene expression [33] while Cas9 nickase (nCas9) that could create a gap in single DNA sequence only loss the partial functions of nuclease activity [34]. One year later after developing dCas9, the same lab fused transcription factors with dCas9 to amplify gene expression, namely CRISPR activation (CRISPRa)[35]. In addition, more accurate and safer CRISPR/Cas9-based gene-editing techniques without introducing DSBs, like base editing[36,37] and prime editing[38], were also developed. The base editing tools, including cytidine base editor (CBE) and adenine base editor (ABE), usually consist of cytidine deaminase/evolved adenine deaminase-fused nCas9/ dCas9. The CBE realizes the conversion of C-G to T-A while the ABE enables the conversion of A-T to G-C, and the current developed nNme2-CBE system shows higher editing efficiency and flexibility[39]. However, the applications of base editing tools are still limited because they can only exert specific base conversion. Therefore, prime editing tools are developed via fusing engineered reverse transcriptase to dCas9 and adding primer sequences to gRNA (pegRNA) to realize the accurate gene editing with lower off-target effect[38]. Both base editing and primer editing tools are safer than the traditional CRISPR/Cas9 so they are potential to be applied in clinical gene therapy. Interestingly, Zhang F and his colleagues developed CRISPR-associated transposase in 2019, which also achieves gene insertion without DNA cleavage[40]. In terms of gene therapy in vivo, numerous Inducible CRISPR systems were studied, such as photoactivated and chemically induced Cas9 [41,42], and smaller-size CRISPR editing tools were also discovered recently[43].

Apart from that, the RNA-editing technique is also one of the most important aspects because RNA plays an essential role in gene expression and gene regulation. In 2014, Mitchell found CRISPR/Cas9 is possible to target RNA sequences rather than DNA after adding a PAM-presenting oligonucleotide (PAMmer)[44]. Based on Mitchell’s research, Nelles and his colleagues utilized a fluorescent-protein-fused and nuclease-inactive Cas9, a modified...
sgRNA, and a PAMmer to target mRNA sequences and realize intracellular transcript imaging in live cells, which provides a new method to visualize metabolism intracellularly [45]. Moreover, Abudayyeh’s lab reported Cas13a (or C2C2) could target RNA sequences in 2016, suggesting CRISPR systems also protect microbes against RNA viruses [46], and Strutt redesigned CRISPR/Cas9 to target RNA two years later [47]. Finally, the discovery of CRISPR/Cas12a and the recently developed CHyMERa may overcome the challenges of multiple genome editing partly [48, 49].

Fig. 4. A Simplification of CRISPR/Cas9. CRISPR/Cas9 is simplified as a robust gene-editing tool via fusing crRNA (spacer + repeat sequence) with TracrRNA as a single guide RNA (sgRNA). B. Mechanism of CRISPR/Cas9 gene-editing. Cas9 enzyme creates DSBs in the targeted DNA sequence. DSBs are repaired intracellularly via two ways: 1. HDR, DSBs are repaired with donor DNA to construct new DNA. 2. NEHJ, DSBs are repaired randomly, and random indels are introduced.

N. Guo, Ji-Bin Liu, W. Li et al. Journal of Advanced Research 40 (2022) 135–152
Application of CRISPR/Cas9 in non-cancerous disease

Genetic hemolytic diseases

Sickle cell disease (SCD) is a typical and severe monogenetic disease due to β-globin (HBB) gene mutation, which causes the generation of abnormal HbS rather than the normal HbA. In the condition of low pressure of oxygen, HbS molecules interact with each other and form spiral-shaped polymers, leading to the sickle deformation of erythrocytes. The symptoms of SCD patients are unobvious in the initial three months after birth due to the presence of fetal hemoglobin (HbF), which is a kind of normal hemoglobin but is only expressed during the fetal period. Therefore, the strategies of SCD treatment mainly include correcting the β-globin gene to produce normal HbA and editing related regulatory genes to induce the reexpression of HbF.

In the aspect of the first strategy, Dever and DeWitt corrected the β-globin gene in patient-derived hematopoietic stem and progenitor cells (HSPCs) by CRISPR/Cas9 separately in 2016 and acquired great results in several weeks followed[50,51]. Two years later, the CRISPR/Cas9 delivery approach was optimized by Charlesworth using adeno-associated virus (AAVs) with post-electroporation[52]. To reduce the off-target effect and increase editing efficiency, reengineered Cas9s were applied widely to edit genes in HSPCs. For example, Park utilized SpyCas9, a high-fidelity Cas9 enzyme with less off-target effect[53], to correct the β-globin gene, and Anzalone exerted gene-editing without DSBs by prime editing tool[38].

Except for direct β-globin gene correction, some research also edits related regulatory elements to relieve the patient’s symptoms. As mentioned above, HbF, a normal but short-term-expressing hemoglobin, has the same functions as HbA and is considered another effective method to treat SCD. As described by Wu and Métais, the disruption of the BCL11A enhancer and HBG1/HBG2 gene promoter by CRISPR/Cas9 leads to HbF reexpression, which provides a novel therapeutic strategy for SCD[54,55]. Recently, the LRF-binding site of BCL11A was also identified as a potential therapeutic target of SCD[56]. Furthermore, the treatment of SCD by CRISPR/Cas9 has entered clinical phases, including one clinical survey (NCT03167450) and five clinical trials[16] (NCT03655678, NCT04819841, NCT04208529, NCT03745287, NCT04774536) (from clinicaltrials.gov, accessed 2021-Jun-09).

Similar to SCD, β-thalassemia, another rare but severe monogenetic disease, is also mainly caused by the abnormal expression of β-globin. Therefore, the reexpression of HbF is a therapeutic strategy for β-thalassemia as well. To induce the production of γ-globin (one of HbF precursors), the 200 bp genomic region of the BCL11A enhancer was also knocked out[57], and 13 kb of the β-globin locus was detected in HSPCs via designing CRISPR systems for both upstream and downstream cleavage points[58], providing the experimental evidence for the application of CRISPR/Cas9 in β-thalassemia treatment. With the development of the related study, some research is nearing the clinical trial stage (NCT03655678, NCT03728322, NCT04925206, NCT04208529) (from clinicaltrials.gov, accessed 2021-Jun-09). Noticeably, the CRISPR/Cas9 based SCD/β-thalassemia CTX001 drug developed by Vertex Pharmaceuticals (NCT03655678, NCT03745287, and NCT04208529) has been applied to treat ten patients recently (seven with transfusion-dependent β-thalassemia and three with SCD). Despite some moderate side effects, the HbF levels of the initial two patients (one with transfusion-dependent β-thalassemia and one with SCD) are increased significantly in more than 99% pancellularity during a 12-month follow-up period[16].

X-linked diseases

Duchenne muscular dystrophy (DMD), one of the X-linked diseases, is caused by dystrophin gene frame-disrupting mutations.
### Genetic hemolytic diseases

| NCT Num.        | Indications          | Intervention/treatment               | Status          | Phase | Sponsor/ Collaborators                                                                 | Start date | Results                                                                 |
|-----------------|----------------------|--------------------------------------|-----------------|-------|----------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|
| NCT04774536     | SCD                  | Drug: CRISPR_SCD001                  | Recruiting      | 1, 2  | University of California, Los Angeles; University of California, Berkeley.              | Dec/01/2021| No Results Posted                                                      |
| NCT03167450     | SCD                  | Opinion survey                       | Completed       | --    | National Human Genome Research Institute (NHGRI)                                        | Apr/28/2017| No Results Posted                                                      |
| NCT03655678     | Beta-Thalassemia     | Biological: CTX001                   | Recruiting      | 1, 2  | Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics                                | Sep/14/2018| More than 99% pancellularity of two patients treated with CTX001 have dramatically increased HbF levels during 12 months. Adverse events include pneumonia in the presence of neutropenia, VOD–SOS, sepsis in the presence of neutropenia, cholelithiasis, and abdominal pain[15]. |
| NCT03745287     | SCD                  |                                       | Recruiting      | 1, 2  |                                       | Nov/27/2018| No Results Posted                                                      |

### Acquired immunodeficiency syndrome

| NCT Num.        | Indications          | Intervention/treatment               | Status          | Phase | Sponsor/ Collaborators                                                                 | Start date | Results                                                                 |
|-----------------|----------------------|--------------------------------------|-----------------|-------|----------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|
| NCT04208529     | Beta-Thalassemia; SCD| Long-term Follow-up Study in Subjects Who Received CTX001 | Enrolling by invitation | --    | Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics                                | Jan/25/2021| No Results Posted                                                      |
| NCT03728322     | Beta-Thalassemia     | Biological: iHSCs treatment group    | Unknown         | 1     | Allife Medical Science and Technology Co., Ltd.                                         | Jan/01/2019| No Results Posted                                                      |
| NCT04925206     | Beta-Thalassemia     | Biological: ET-01                    | Not yet recruiting | 1    | EdiGene (GianZhao) Inc.                                                               | Aug/17/2021| No Results Posted                                                      |
| NCT04819841     | SCD                  | Genetic: GPH101 Drug Product         | Not yet recruiting | 1, 2  | Graphite Bio, Inc.                                                                      | Sep/01/2021| No Results Posted                                                      |

### Ocular diseases

| NCT Num.        | Indications          | Intervention/treatment               | Status          | Phase | Sponsor/ Collaborators                                                                 | Start date | Results                                                                 |
|-----------------|----------------------|--------------------------------------|-----------------|-------|----------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|
| NCT04560790     | Viral Keratitis Herpes; Simplex Virus Infection. | Drug: BD111 Adult single group Dose  | Active, not recruiting | 1, 2  | Eye & ENT Hospital of Fudan University Editas Medicine, Inc.                               | Nov/04/2020| No Results Posted                                                      |
| NCT03872479     | Congenital Amaurosis 10 | Drug: EDIT-101                       | Recruiting      | 1, 2  | University Hospital, Montpellier; Association Francaise contre les Myopathies Telethon.  | Sep/26/2019| No Results Posted                                                      |

### Neurodegenerative diseases

| NCT Num.        | Indications          | Intervention/treatment               | Status          | Phase | Sponsor/ Collaborators                                                                 | Start date | Results                                                                 |
|-----------------|----------------------|--------------------------------------|-----------------|-------|----------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|
| NCT03855631     | Kabuki Syndrome 1    | Genetic: Intervention on primary cultured cells | Completed       | --    | University Hospital, Montpellier; Association Francaise contre les Myopathies Telethon.  | Sep/28/2020| No Results Posted                                                      |

### Others

| NCT Num.        | Indications          | Intervention/treatment               | Status          | Phase | Sponsor/ Collaborators                                                                 | Start date | Results                                                                 |
|-----------------|----------------------|--------------------------------------|-----------------|-------|----------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------|
| NCT04535648     | Enterovirus Infections | Other: Non-invasive detection method: CRISPR technology | Not yet recruiting | --    | Children's Hospital of Fudan University                                                   | Oct/01/2021| No Results Posted                                                      |
| NCT04178382     | Severe Sepsis        | Diagnostic Test: PCR-CRISPR / Cas12a detection | Unknown         | Not Applicable | Chinese Medical Association                                                             | Aug/01/2019| No Results Posted                                                      |
| NCT04074369     | Tuberculosis         | Diagnostic Test: CRISPR-based Test    | Unknown         | --    | Huashan Hospital; Wenzhou Central Hospital; Hangzhou Red Cross Hospital.                | May/01/2019| No Results Posted                                                      |
| NCT04535505     | Pertussis            | Diagnostic Test: Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug-resistant genes of erythromycin by CRISPR technology | Not yet recruiting | --    | Children's Hospital of Fudan University                                                  | Jan/01/2022| No Results Posted                                                      |
Dystrophin gene exists in x-chromosome and mutant DMD gene is recessive, so the percent of male DMD patients is significantly higher while the female are usually carriers without significant symptoms. To explore the effective therapeutic strategies of DMD, in 2016, Long and his colleagues utilized CRISPR/Cas9 to skip the mutated dystrophin exons in vivo via AAV vectors, which causes the expression of dystrophin protein[59]. Similar results were also acquired in the same year by Nelson and Tabebordbar after removing exon 23 of the dystrophin gene[60,61]. In later 2018, Ryu corrected the dystrophin gene precisely using base editing tools, which provides a safer method of DMD treatment[62].

Except for DMD, CRISPR/Cas9 techniques also provide a great chance to treat other severe X-linked diseases. For example, Kuo reported knocking in the cDNA of CD40 ligand by CRISPR/Cas9 could treat X-Linked Hyper-IgM Syndrome (XHIM)[63]. Moreover, the correction of the CYBB gene in HSPCs is one of the potential therapeutic strategies for X-linked chronic granulomatous disease (X-CGD)[64]. Recently, Pavel-Dinu’s group demonstrated the effective therapy of X-linked severe combined immunodeficiency (SCID-X1) could be achieved by integrating a corresponding cDNA in long-term hematopoietic stem cells (LT-HSCs) using CRISPR/Cas9[65]. Similarly, Goodwin also edited the forkhead box protein 3 (FOXP3) gene by CRISPR/Cas9 for immune dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome treatment, which suggested gene correction by CRISPR/Cas9 is one of the most promising therapeutic approaches to genetic autoimmune diseases[66].

**Acquired immunodeficiency syndrome**

Acquired immunodeficiency syndrome (AIDS) is an untreatable disease caused by human immunodeficiency virus infection (HIV). The discovery and development of CRISPR/Cas9 techniques bring potential strategies against HIV infection. In the process of HIV infection, long terminal repeat (LTR) promoter plays a vital role in HIV gene expression, which is considered one of the therapeutic targets. Therefore, Ebina firstly edited the LTR promoter by CRISPR/Cas9 in 2013, causing the significant decrease of LTR-driven expression[67]. One year later, Hu and his colleagues also inactivated the HIV expression in infected microglial, promonocytic, and T cells by editing the LTR U3 region[68]. The recently developed CRISPR system was also applied for HIV treatment, such as CRISPR-Cas12a, a more active and specific CRISPR system. It was utilized by Gao to target and cleave the LTR sequence without pure DNA insertions[69]. Apart from LTR, the pol gene and tat/rev gene were also identified as therapeutic targets and inactivated by CRISPR/Cas9, inhibiting the expression of HIV genes to a different extent[70]. And Kaminski removed the whole HIV genome ex vivo to reduce the viral load in CD4[+] T cells[71]. Noticeably, in 2017, Yin’s lab exerted CRISPR/Cas9-based editing of LTR and Gag/Pol gene in vivo by AAV delivery and reduced HIV RNA expression successfully, which promotes the development of Cas9-based HIV therapy significantly.

Moreover, gene editing of coreceptors is another approach to reducing or eliminate HIV infection except editing the HIV genome. As a typical example, CCR5 of human CD4[+] cells was silenced by CRISPR/Cas9 in 2014, making CD4[+] cells acquire resistance against HIV[72]. After three years, Xu transplanted the CCR5-ablated CD34[+] HSPCs into mice, causing enrichment of CD4[+] T cells and a dramatic decrease in viral titration[73], and similar results were also acquired in 2019 using saCas9[74]. In addition, Liu also tried to edit coreceptors CXC4 and CCR5 together in CD4[+] T cells by CRISPR/Cas9 using ‘all in one’ vector to reduce HIV infections[75]. Apart from that, Teng and his colleagues deleted mir-146a genomic sequences, whose transcriptional products suppress innate immune, to activate the immune system and limit HIV replication[76].

Following the development of CRISPR/Cas9 techniques and the comprehensive understanding of HIV, the potential of Cas9-based HIV therapy has been studied intensely. In early 2015, Zhu had detected ten possible targets of the HIV-1 genome for CRISPR/Cas9 and demonstrated the second exon (T10) of the Gag/Pol gene in vivo by AAV delivery and reduced HIV RNA expression successfully, which promotes the development of Cas9-based HIV therapy significantly.

**Cardiovascular diseases**

Cardiovascular diseases (CVDs) are the major cause of death globally, accounting for 32% of all deaths in 2019. According to

| NCT Num. | Indications | Intervention/treatment | Status | Phase | Sponsor/ Collaborators | Start date | Results |
|----------|-------------|------------------------|--------|-------|------------------------|------------|---------|
| NCT04990557 | COVID-19 Respiratory Infection | Drug: PD-1 and ACE2 Knockout T Cells | Not yet recruiting | 1, 2 | Kafrelsheikh University | Aug/01/2021 | No Results Posted |
| NCT03342547 | Gastrointestinal Infection | Procedure: Duodenal biopsy Procedure: Saliva | Unknown | Not Applicable | Chinese University of Hong Kong | Apr/18/2011 | No Results Posted |
| NCT046501051 | Hereditary Transthyretin Amyloidosis | Biological: NTLA-2001 | Recruiting | 1 | Intellia Therapeutics | Nov/05/2020 | Patients treated by NTLA-2001 showed decreased serum transthyretin protein concentrations (mean reduction: 52 ± 3) with mild adverse events[79]. |
| NCT04478409 | Familial Mediterranean Fever Rubinstein-Taybi Syndrome | Biological: one additional blood sample during a planned blood test | Not yet recruiting | – | Hospices Civils de Lyon | Nov/01/2020 | No Results Posted |
| NCT04122742 | | Biological: Culture of lymphoblastoid line from blood sample | Recruiting | – | University Hospital, Bordeaux | Oct/08/2019 | No Results Posted |
Ding’s and Wang’s reports, the destruction of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene by Cas9 in vivo reduced low-density lipoprotein cholesterol levels while strengthening the prevention of CVDs[79,80].

In 2018, Chadwick and his colleagues utilized CRISPR-engineered base editors to introduce nonsense mutations in vivo, resulting in a significant decrease of PCSK9 (about 50%) and plasma cholesterol level (about 30%)[81]. Recently, the knockdown of PCSK9 by CRISPR-engineered base editors in primates achieved great success. After a single injection of lipid nanoparticles containing CRISPR modules, the level of PCSK9 protein remains at only 10% of their original level for ten months, which may provide a convenient therapeutic approach for CVDs patients in the future[82]. Apart from PCSK9, ANGPTL3 is also associated with CVDs. Therefore, Chadwick’s lab reduced the level of low-density lipoprotein cholesterol and blood triglycerides by CRISPR-induced ANGPTL3 mutations, which decreases the possibility of coronary heart disease[83].

In terms of myocardial infarction (MI), Cho integrated the LEF1 gene into human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) then transplanted them into rat models, which increases the survival significantly[84]. In addition, a current study demonstrated that inhibiting the expression of the calmod2 gene by CRISPRi could treat Calmodulinopathies, a new kind of genetic arrhythmia syndrome, suggesting the potential clinical application of CRISPRi inhibitors[85].

Ocular diseases

CRISPR/Cas9 has been evidenced its potential to be applied in some genetic ocular diseases therapy, including cataracts, retinitis pigmentosa (RP), aniridia, and proliferative vitreoretinopathy (PVR). The earliest application of CRISPR/Cas9 in ocular diseases is to correct the Crygc gene in mouse to treat cataracts in 2013[86]. Then it is widely used in RP treatment. For example, Bassuk repaired the GTPase regulator (RPGR) gene ex vivo[87], while Bakondi and Giannelli edited S334ter and P23H mutation of the rhodopsin (RHO) gene in vivo separately[88,89], to explore the therapeutic strategy of RP. And the last two studies in RHO results in the restoration of visual function and the slowdown of photoreceptor degeneration, suggesting CRISPR/Cas9 could be used in RP treatment[88,89].

Additionally, Mirjalili Mohanna successfully created a biological model for aniridia, then developed a strategy for its therapy by editing the Sey gene using CRISPR/Cas9[90]. Proliferative vitreoretinopathy (PVR) also benefits from the CRISPR/Cas9 techniques. As reported by Yang, deleting the gene of platelet-derived growth factor receptor β (PDGFRβ) in retinal pigment epithelial cells is a potential strategy for PVR treatment[91]. According to clinicaltrials.gov, two projects (NCT04560790 and NCT03872479) have been processed into clinical trials for ocular disease treatment (from clinicaltrials.gov, accessed 2021 -Jun-09).

Fig. 5. Cancer targets that CRISPR/Cas9 is applied to. CRISPR/Cas9 is applied to screen cancerous novel therapeutic targets and drug resistance genes. And disrupting oncogenes or correcting tumor suppressor genes are routine and direct strategies to treat cancers. Furthermore, it is also effective to relieve cancer symptoms by editing cancer-related regulator genes, tumor microenvironment-associated genes, anti-apoptosis genes, cancer-related epigenetic genes and other related DNA sequences. Some studies also insert suicide genes to induce apoptosis of cancer cells. Moreover, CIRPSR/Cas9 is utilized to improve immunotherapy especially CAR-T therapy, and Cas9-based gene editing could prevent virus-induced cancers. Virus-induced cancers are potentially caused by HPV, HBV, HCV and EBV. Their effective targets are E6 and E7 oncogenes for HPV, HBsAg, cccDNA, S and X genes for HBV, viral RNA for HCV, and viral genome and promoter region of BART for EBV.

N. Guo, Ji-Bin Liu, W. Li et al. Journal of Advanced Research 40 (2022) 135–152

142
Neurodegenerative diseases

Neurodegenerative diseases (NDDs), such as Alzheimer’s disease (AD) and Huntington disease (HD), result from the death or function loss of the neurocytes. For the application of CRISPR/Cas9 in AD, Wadhwani corrected the E4 allele of the apolipoprotein E gene (APOE) to the E3 isofrom in stem-cell-derived neurons to decrease the phosphorylated tau production, which reduces the risk of AD significantly[92]. Moreover, CRISPR/Cas9 technique also provides a great chance to study the mechanism of AD further. For example, utilizing CRISPR/Cas9, Chiu demonstrated integrin-binding protein 1 (IB1) might negatively regulate the production of amyloid β peptide, a protein associated with AD[93]. In addition, after deleting the SORL1 gene, a selective effect on AD symptoms was observed, including endosome enlargement in human-induced pluripotent stem cells (hiPSC) neurons but not in hiPSC microglia, which further elucidated the pathogenesis of AD[94].

HD is another neurodegenerative disorder caused by CAG repeat expansion of the huntingtin gene (HTT). Therefore, Shin and Kolli inactivated the mutant allele to block the mutated HTT mRNA and protein generation in an in vitro model of HD[95,96], whereas Yang exerted Cas9-mediated suppression of endogenous mHTT in a mouse model[97]. Recently, six prevalent SNPs and all suitable PAM motifs of HTT exon-1 have been identified, facilitating further research on the treatment of HD[98]. Apart from that, CRISPR/Cas9 also provides a possible therapeutic strategy for Friedreich’s ataxia (FRDA). For example, removing the GAA expansions of the frataxin gene (FXN) in vitro and in vivo alleviates related symptoms dramatically but with some unexpected side effects like p53-mediated cell proliferation delay[99]. At present, an increasing number of researchers pay more attention to NDDs research due to the apparent aging of the population in some countries. However, further studies are still needed for the more specific pathology and more effective Cas9-based treatment. (Fig. 5, Table 2)

Application of CRISPR/Cas9 in cancers

Cancer targets screening

Due to the capability of knocking genes out efficiently, CRISPR/Cas9 techniques developed as one of the most powerful tools to screen cancer targets. Compared with the screen approach via blocking gene expression by RNAi, CRISPR-mediated screen provides a strategy to efficiently identify more lethal genes and protein domains, causing a significant acceleration of cancer target discovery[100,101].

Benefiting from the development of the CRISPR technique, a number of novel therapeutic targets have been identified. For example, in 2015, Shi reported 19 unknown dependencies in acute myeloid leukemia cells (AMLs) after targeting the exons of 192 chromatin regulatory domains by Cas9. And in the next two years, more therapeutic targets were discovered due to wider CRISPR-based genome screens, including KAT2A in AML and chromatin remodeling protein INO80 in mutant KRAS colorectal cancers[102,103]. Remarkably, a novel oncogene, namely KPNB1, was identified by Kodama in 2017, which provides a new therapeutic target for epithelial ovarian cancer (EOC)[104]. Currently, Zhang’s lab utilized CRISPR/Cas9 to make clear the mechanism of NSD1 and identified it as a novel target for human hepatocellular carcinoma (HCC)[105]. Furthermore, following the recent combination of computer data analysis and genetic screens, more efficient and comprehensive screen systems, such as CERES and DrugTargetSeq[106,107], have been established. For instance, after analyzing the different dimensionalities of screen data, Behan demonstrated Werner syndrome ATP-dependent helicase is a lethal target in cancers[108], and Gurusamy identified p38 Kinase as an immunotherapeutic target[109].

In addition, the genetic screens based on CRISPR/Cas9 also reveals several genes related to the resistance of anti-cancer drugs. For example, for vemurafenib, an RAF inhibitor, Shalem utilized Cas9-mediated knockout screens to identify potential targets, including validated MED12 and NF1 genes as well as novel NF2, CUL3, TADA2B, and TADA1 genes[110]. Similarly, the mechanisms of ispinesib, YM155, selinexor, and topoisomerase II resistance were illustrated, providing the guidelines for further developing anti-cancer drugs[107,111,112]. Noticeably, Xu reported the depletion of the ELPS gene blocks U34 tRNA modification to inhibit the translation of hnRNQ mRNA, which reveals ELPS plays a determinant role in gemcitabine sensitivity in gallbladder cancer[113].

The application of CRISPR/Cas9 provides a robust and efficient approach to screen cancer targets. However, there is no denying that some problems are present and remain unsolved. The high rate of false-positive results is the major one among them. As reported by Aguirre, the number of edited genes in cells is related to cell viability, which means the death or inaction of cells may be caused by the process of Cas9-mediated gene editing rather than the mutated genes[114]. To overcome the problem, except for the further development of computational correction and data analysis, the discovery or construction of more effective CRISPR/Cas9 delivery strategies that do not affect cell viability are also essential.

Cancer treatment

Traditionally, cancers are considered as the results of some mutated genes after being stimulated by carcinogens. Therefore, gene editing by CRISPR/Cas9 is a potential approach to fight against or even cure cancers. As a typical example, disrupting the most frequent mutated oncogene KRAS by Cas9 significantly reduces the viability of the cancer cells in vitro and the growth of tumors in vivo[115,116], and similar results were also acquired using CRISPRi to block KRAS expression[117]. Moreover, other oncogenes, such as the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer, were knocked out and achieved success in different degrees[118].

Apart from oncogenes, the mutation of tumor suppressor genes also plays an essential role in canceration. For instance, the mutation of mixed-lineage leukemia 3 (MLL3) gene promotes leukemogenesis[119], and the correction of the protein kinase C (PKC) gene suppresses tumor growth[120]. Furthermore, the disruption of the most well-known tumor suppressor genes p53 and pten alone or in combination by Cas9 has been proved to significantly induce various cancers[121-123], which suggests correcting the tumor suppressor genes may reverse the cancers or treat cancers[124].

In addition, as reported by Gao, the concurrent knock-in of oncogene Nras and disruption of suppressor gene Pten induced liver cancer, revealing that the oncogenes and tumor suppressor genes are the direct and major therapeutic targets for cancer treatment[125].

Viral infection is also one of the reasons for canceration. For example, it is well-known that human papillomaviruses (HPVs) infection results in cervical carcinoma, so the HPV vaccines are applied widely to prevent cervical carcinoma. However, vaccines are useless for patients who have been infected HPVs or suffer from cervical carcinoma, while CRISPR-mediated gene editing may provide a potential strategy to fight against HPVs. As reported by Hu and Kennedy, CRISPR/Cas9 could disrupt HPV oncogenes E6 and E7 in vitro, causing infected cell cycle arrest and apoptosis[126,127]. The in vivo experiment also evidenced the accessibility of cervical carcinoma treatment via targeting HPV E6 and E7 by...
| NCT Num.         | Indications                                                                 | Intervention/treatment                                                                 | Status           | Phase | Sponsor/ Collaborators                                                                 | Start date    | Results                                                                 |
|------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------|-------|----------------------------------------------------------------------------------------|---------------|------------------------------------------------------------------------|
| NCT03057912      | Human Papillomavirus-Related Malignant Neoplasm                              | Biological: TALEN Biological: CRISPR/Cas9.                                              | Unknown          | 1     | First Affiliated Hospital, Sun Yat-Sen University; Jingchu University of Technology.   | Jan/ 15/ 2018 | No Results Posted                                                      |
| NCT04426669      | Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Gastrointestinal Cancer; Colo-rectal Cancer; Pancreatic Cancer; Gall Bladder Cancer; Colon Cancer; Esophageal Cancer; Stomach cancer. | Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-Infiltrating Lymphocytes (TIL); Drug: Aldesleukin. | Recruiting       | 1, 2  | Intima Bioscience, Inc.; Masonic Cancer Center, University of Minnesota.               | May/ 15/ 2020 | No Results Posted                                                      |
| NCT03399448      | Multiple Myeloma; Melanoma; Synovial Sarcoma; Myxoid/Round Cell Liposarcoma. | Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited enogenous TCR and PD-1; Drug: Cyclophosphamide; Drug: Fludarabine; Device: NY-ESO-1 expression testing. | Terminated       | 1     | University of Pennsylvania; Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics. | Sep/ 05/ 2018 | CRISPR/Cas9 exerts gene editing in human-derived T cells with 40% single mutation, 20% double mutation, and 10% triple mutation. Injecting CRISPR-engineered T cells shows long-term persistence and high-level engraftment.[17]. |
| NCT03545815      | Solid Tumor                                                                  | Biological: anti-mesothelin CAR-T cells                                                 | Recruiting       | 1     | Chinese PLA General Hospital                                                            | Mar/ 19/ 2018 | No Results Posted                                                      |
| NCT04037566      | Acute Leukemia Lymphocytic                                                   | Genetic: XYYF19 CAR-T cell; Drug: Cyclophosphamide; Drug: Fludarabine.                  | Recruiting       | 1     | Xijing Hospital                                                                        | Aug/ 01/ 2019 | No Results Posted                                                      |
| NCT04244656      | Multiple Myeloma                                                             | Biological: CTX120                                                                       | Recruiting       | 1     | CRISPR Therapeutics AG                                                                  | Jan/ 22/ 2020 | No Results Posted                                                      |
| NCT04438083      | Renal Cell Carcinoma                                                         | Biological: CTX130                                                                       | Recruiting       | 1     | CRISPR Therapeutics AG                                                                  | Jun/ 16/ 2020 | No Results Posted                                                      |
| NCT04502446      | T Cell Lymphoma                                                              | Biological: CTX130                                                                       | Recruiting       | 1     | CRISPR Therapeutics AG                                                                  | Jul/ 31/ 2020 | No Results Posted                                                      |
| NCT04036943      | B-cell Malignancy; Non-Hodgkin Lymphoma; Adult B Cell ALL.                   | Biological: CTX110                                                                       | Recruiting       | 1     | CRISPR Therapeutics AG                                                                  | Jul/ 22/ 2019 | No Results Posted                                                      |
| NCT04637763      | Myeloid/Non-Hodgkin Lymphoma; Myxoid/Round Cell Liposarcoma.                | Genetic: CB-010; Drug: Cyclophosphamide; Drug: Fludarabine.                             | Recruiting       | 1     | Caribou Biosciences, Inc.                                                               | May/ 26/ 2021 | No Results Posted                                                      |
| NCT04557436      | B Acute Lymphoblastic Leukemia                                               | Drug: PBLT52CAR19                                                                       | Recruiting       | 1     | Great Ormond Street Hospital for Children NHS Foundation Trust; University College, London. | Aug/ 12/ 2020 | No Results Posted                                                      |
| NCT03174965      | Solid Tumor                                                                  | Biological: Mesothelin-directed CAR-T cells                                             | Unknown          | 1     | Chinese PLA General Hospital                                                            | Nov/ 01/ 2018 | No Results Posted                                                      |
| NCT03166878      | B Cell Leukemia; B Cell Lymphoma                                             | Biological: UCART019                                                                     | Recruiting       | 1, 2  | Chinese PLA General Hospital                                                            | Jun/ 01/ 2017 | No Results Posted                                                      |
| NCT03606486      | High-Grade Ovarian Serous Adenocarcinoma                                     | Other: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Device: Lavage; Other: Pap Smear. | Recruiting       | Not Applicable | University of Washington; Minnesota Ovarian Cancer Alliance. | Nov/ 16/ 2018 | No Results Posted                                                      |
| NCT03081715      | Esophageal Cancer                                                            | Other: PD-1 Knockout T Cells                                                            | Completed        | Not Applicable | Hangzhou Cancer Hospital; Anhui Redgene Biotechnology Co., Ltd. | Mar/ 14/ 2017 | No Results Posted                                                      |
| NCT03332030      | Neurofibromatosis Type 1; Tumors of the Central Nervous System.              | Diagnostic Test: Collection of Stem Cells                                               | Suspended        | –     | Roger Packer                                                                           | Nov/ 27/ 2015 | No Results Posted                                                      |
Cas9. After introducing indels in E6 and E7, the dramatical inhibition of tumorigenesis and tumor growth was observed[128], and the treatment combining with cis-diamine-dichloro platinum II (CDDP)[129]. Moreover, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are also risky, causing almost 80% of hepatocellular carcinoma (HCC) in the world. According to previous studies, high HBV surface antigen (HBsAg) is highly related to HBV-associated HCC development, so Zhen and Song knocked out the HBsAg gene to inhibit HBV expression and replication[130,131]. Remarkably, Song clarified the pathway of HBsAg in HCC development in 2018, which ensures the anti-cancer effect of disrupting the HBsAg gene theoretically[131]. Apart from HBsAg, utilizing CRISPR/Cas9, Seeger disrupted covalently closed circular DNA (cccDNA) to inhibit HPV infections up to eightfold[132], whereas Zhu targeted HBV and HCV infections up to eightfold[132], whereas Zhu targeted HBV and HCV infections up to eightfold[132].

Additionally, an increasing number of studies pay more attention to the Epstein-Barr virus (EBV) because EBV infection is highly related to many malignancies. Some research reported that a dramatic inhibition of EBV, including proliferation arrest and viral load decrease, was observed after targeting the viral genome or promoter region of BamHI A rightward transcript (BART) through CRISPR/Cas9[135–137], which reduces the risk of cancertation effectively. Although the infection of these viruses does not mean cancers absolutely, decreasing or removing viral load is a robust approach to prevent or treat cancers, and CRISPR/Cas9 is one of the robust tools to achieve that.

However, except for genes that cause cancers directly, some genes that promote tumor growth or prevent apoptosis of tumor cells are also identified as treatment targets for cancers. For example, vascular endothelial growth factor A (VEGFA) is a tumor microenvironment-associated gene highly expressed in osteosarcoma (OS), while CD44 is highly related to tumor progression and metastasis, and their Cas9-mediated disruptions inhibit OS and metastasis significantly[138,139]. The DNMT1 gene was targeted by CRISPR/Cas9 due to the high level of aberrant methylation in tumor cells, causing the slowing down of tumor growth in vivo[140]. Then in recent two years, Li used CRISPR-engineered base
editor to edit mutated TERT promoters to suppress brain tumor growth[141], and Singhal demonstrated knocking Ral-interacting protein (RIP) gene out relieves the effect of the p53 mutation [142]. Noticeably, long non-coding RNA (IncRNA) has been proved as an up regulator in bladder cancer. After targeting IncRNA by CRISPR/Cas9, the proliferation, migration, and invasion of tumors were suppressed dramatically[143]. Apart from tumor regulator genes, some researchers also disrupted anti-apoptosis genes, such as MTH1 and MCL1, to induce the apoptosis of cancer cells [144,145]. Interestingly, Chen harnessed CRISPR/Cas9 to insert herpes simplex virus type 1 thymidine kinase (HSV1-tk) sequence, a suicide gene, causing the decrease of tumor size successfully, which suggests suicide-gene insertion by Cas9 may be a potential approach to treat cancers [146].

In recent years, immune therapy, especially CAR-T therapy, has been considered one of the most promising approaches to treat cancers. Generating allogeneic universal CAR-T cells from healthy donors is one of the most feasible and durable strategies[147]. Fully allogeneic CAR-T cells need to knock out TCR and HLA and transduce CAR simultaneously, so flexible and efficient CRISPR/Cas9 approaches to treat cancers[146].

Moreover, some genes like immune system genes, some researchers also disrupted anti-apoptosis genes, such as MTH1 and MCL1, to induce the apoptosis of cancer cells [144,145]. Interestingly, Chen harnessed CRISPR/Cas9 to insert herpes simplex virus type 1 thymidine kinase (HSV1-tk) sequence, a suicide gene, causing the decrease of tumor size successfully, which suggests suicide-gene insertion by Cas9 may be a potential approach to treat cancers [146].

In recent years, immune therapy, especially CAR-T therapy, has been considered one of the most promising approaches to treat cancers. Generating allogeneic universal CAR-T cells from healthy donors is one of the most feasible and durable strategies[147]. Fully allogeneic CAR-T cells need to knock out TCR and HLA and transduce CAR simultaneously, so flexible and efficient CRISPR/Cas9 approaches to treat cancers[146].

Apart from physical strategy, researchers also deliver CRISPR/Cas9 via different vectors. According to the types of vectors, the method of CRISPR/Cas9 delivery could be divided into two kinds: viral strategies and non-viral strategies. Considering the more-ordinary delivery and targeting ability, viruses are usually utilized and engineered to deliver CRISPR/Cas9. Adeno-associated virus (AAV) is the commonest vector for gene therapy in vivo and ex vivo due to its wide serotype, little immunogenicity, and toxicity[159], but the small payload (only 4.5–5 kb) limits its development. Compared with AAV, lentivirus (LV) and adenovirus (AdV) have a better capacity and allow delivery of additional genetic compounds, such as multiple promoters. Thereinto, one of the biggest advantages of AdV is its ability to transfer a wider range of cells than LV and AAV. However, the bigger sizes of LV and AdV could trigger strong humoral and even cellular immune responses, which suggests low efficiency of delivery and potential risk of inflammation[154]. Other viral vectors are also applied recently and have their own characteristics respectively. For example, EBV vectors are able to express exogenous genes more stably [160], and Sendai viral vectors are capable of infecting broader host types[161], while Baculovirus vectors have a bigger payload[162]. However, these vectors are only used ex vivo by now, but they are still potential to be applied in vivo in the future after optimizing.

Problems of CRISPR/Cas9

Delivery challenge

Although CRISPR/Cas9 is a mature gene editing technology and has been used widely, therapeutic CRISPR/cas9 maintains many problems due to the off-target effect, low efficiency, and packaging challenges. In terms of CRISPR-based gene therapy, the difficulties of the delivery system in vivo are highlighted mainly[153]. An ideal delivery method for therapeutic CRISPR/cas9 should have the features of high delivery efficiency, great targeting ability, and ease of mass production. However, the current strategies are still far from reaching the ideal bay[154].

Physical strategies of CRISPR/Cas9 delivery are usually applied in vitro or ex vivo but rare in vivo. Except for traditional electroporation and microinjection, more efficient methods, including ultrasound-propelled nanomotors[155], microfluidic or nanofluidic approaches[156], and lance assay nano injection[157] are also utilized to deliver CRISPR systems. But for the CRISPR/Cas9 mediated-gene-editing in human primary immune cells, electroporation is still the first choice in several studies[48]. Interestingly, some physical approaches is able to deliver CRISPR/Cas9 in vivo. For example, hydrodynamic injection (HDI) was reported as a novel approach to CRISPR system delivery[158], but its application is limited to a few organs, such as the liver, because the method may cause damage during delivery.

Apart from physical strategy, researchers also deliver CRISPR/Cas9 via different vectors. According to the types of vectors, the method of CRISPR/Cas9 delivery could be divided into two kinds: viral strategies and non-viral strategies. Considering the more-extraordinary delivery and targeting ability, viruses are usually utilized and engineered to deliver CRISPR/Cas9. Adeno-associated virus (AAV) is the commonest vector for gene therapy in vivo and ex vivo due to its wide serotype, little immunogenicity, and toxicity[159], but the small payload (only 4.5–5 kb) limits its development. Compared with AAV, lentivirus (LV) and adenovirus (AdV) have a better capacity and allow delivery of additional genetic compounds, such as multiple promoters. Thereinto, one of the biggest advantages of AdV is its ability to transfer a wider range of cells than LV and AAV. However, the bigger sizes of LV and AdV could trigger strong humoral and even cellular immune responses, which suggests low efficiency of delivery and potential risk of inflammation[154]. Other viral vectors are also applied recently and have their own characteristics respectively. For example, EBV vectors are able to express exogenous genes more stably [160], and Sendai viral vectors are capable of infecting broader host types[161], while Baculovirus vectors have a bigger payload[162]. However, these vectors are only used ex vivo by now, but they are still potential to be applied in vivo in the future after optimizing.

-Problems of CRISPR/Cas9

Delivery challenge

Although CRISPR/Cas9 is a mature gene editing technology and has been used widely, therapeutic CRISPR/cas9 maintains many problems due to the off-target effect, low efficiency, and packaging challenges. In terms of CRISPR-based gene therapy, the difficulties of the delivery system in vivo are highlighted mainly[153]. An ideal delivery method for therapeutic CRISPR/cas9 should have the features of high delivery efficiency, great targeting ability, and ease of mass production. However, the current strategies are still far from reaching the ideal bay[154].

Physical strategies of CRISPR/Cas9 delivery are usually applied in vitro or ex vivo but rare in vivo. Except for traditional electroporation and microinjection, more efficient methods, including ultrasound-propelled nanomotors[155], microfluidic or nanofluidic approaches[156], and lance assay nano injection[157] are also utilized to deliver CRISPR systems. But for the CRISPR/Cas9 mediated-gene-editing in human primary immune cells, electroporation is still the first choice in several studies[48]. Interestingly, some physical approaches is able to deliver CRISPR/Cas9 in vivo. For example, hydrodynamic injection (HDI) was reported as a novel approach to CRISPR system delivery[158], but its application is limited to a few organs, such as the liver, because the method may cause damage during delivery.

Apart from physical strategy, researchers also deliver CRISPR/Cas9 via different vectors. According to the types of vectors, the method of CRISPR/Cas9 delivery could be divided into two kinds: viral strategies and non-viral strategies. Considering the more-extraordinary delivery and targeting ability, viruses are usually utilized and engineered to deliver CRISPR/Cas9. Adeno-associated virus (AAV) is the commonest vector for gene therapy in vivo and ex vivo due to its wide serotype, little immunogenicity, and toxicity[159], but the small payload (only 4.5–5 kb) limits its development. Compared with AAV, lentivirus (LV) and adenovirus (AdV) have a better capacity and allow delivery of additional genetic compounds, such as multiple promoters. Thereinto, one of the biggest advantages of AdV is its ability to transfer a wider range of cells than LV and AAV. However, the bigger sizes of LV and AdV could trigger strong humoral and even cellular immune responses, which suggests low efficiency of delivery and potential risk of inflammation[154]. Other viral vectors are also applied recently and have their own characteristics respectively. For example, EBV vectors are able to express exogenous genes more stably[160], and Sendai viral vectors are capable of infecting broader host types[161], while Baculovirus vectors have a bigger payload[162]. However, these vectors are only used ex vivo by now, but they are still potential to be applied in vivo in the future after optimizing.

-Regarding non-viral strategies, liposomes are utilized most frequently because they have been merchandised widely, and some researchers also try to use gold nanoparticles (AuNPs) as the vectors for CRISPR/Cas9 delivery. Other non-viral delivery vectors, including Lipofectamine RNAiMAX[163], PolyJet™ in Vitro DNA Transfection Reagent[126], and X-tremeGENE HP DNA Transfection Reagent[126], are also commercial but are only suitable for in vitro or ex vivo experiments by now. In terms of in vivo delivery, thousands of studies focus on discovering and synthesizing high-efficient and low-cytotoxic non-viral vectors. Present strategies include common nano-sized preparations (e.g., self-assembled micelles[164] and polyethylene glycol phospholipid-modified cationic lipid nanoparticle [165] for CRISPR/Cas9 plasmid delivery, and DNA nanoclew[166] and black phosphorus nanosheets[167] for CRISPR/Cas9 complex delivery), receptor-mediated delivery strategies (e.g., folate receptor-targeted liposomes deliver CRISPR/Cas9 plasmids[140], cell-penetrating peptides (CPPs)-mediated delivery strategies (e.g., Kim fused Cas9 protein with a low molecular-weight protamine and a nuclear localization sequence to deliver CRISPR/Cas9 complex[168], while Wang established modified cationic α-helical polypeptides based PEGylated nanoparticles to deliver CRISPR/Cas9 plasmids and siRNA[169], and multi-model delivery strategies (e.g., R8-GR peptide modified cationic liposome for the delivery of CRISPR/Cas9 and sgRNA plasmids[170], and near-infrared upconversion-activated system for CRISPR/Cas9 complex delivery[171]). Still, a number of troubles in the field of non-viral strategies, like delivery barriers or endo-
some evasion, remain unresolved, which stagnates the further development of therapeutic CRISPR/cas9\[154\].

In addition to various delivery vectors, the forms of cargos also play an important role in CRISPR/Cas9 delivery. Traditionally, Cas9 is delivered in the form of DNA or mRNA with sgRNA and template sequence together. In order to increase gene editing efficiency, Yin and his colleagues delivered Cas9 mRNA by lipid nanoparticles while delivering sgRNA and template sequence by AAV separately\[172\]. Moreover, Cas9 proteins can also be delivered into cells directly by fusion or recruitment methods. It avoids the risk of genome integration and reduces the off-target effect due to the short half-life of Cas9 protein, which is considered a safer approach for gene therapy\[173\]. In conclusion, there is an opposite requirement of cargo loads to carry more CRISPR or expressive modules. Therefore, how to balance these two problems and develop an optimized delivery strategy are the aspects that need to be studied further.

Off-target effect

The off-target effect is one of the CRISPR/Cas9 application limitations and is considered a significant risk factor during gene therapy in vivo. Although several computer software has optimized the design of sgRNA, its specificity cannot be ensured absolutely. Furthermore, except for sgRNA design, the duration of the Cas9 enzyme also plays an important role. Therefore, disposable Cas9 design, such as delivering protein directly, could significantly decrease the off-target effect. In addition, optimized Cas9 enzyme is also an approach to reduce the off-target effect, including SpCas9-HF1\[174\] and eSpCas9\[175\]. However, the off-target effect in vivo keeps unsolved, and it is also highly related to the delivery strategy.

Pam limitation

As described above, the Pam sequence is essential for CRISPR/Cas9 targeting, and only the DNA sequences that contain Pam could be targeted by the Cas9 enzyme. However, Pam limits the design of sgRNA and decreases the flexibility of CRISPR/Cas9 significantly. Although an increasing number of CRISPR types are discovered, causing more Pam fragments are selectable at present. The compulsory Pam insertion still affects the design of sgRNA in some situations. Therefore, how to develop a designable Pam is significant to broaden the application of CRISPR/Cas9.

Immune response

As a foreign protein, Cas9 may induce the immune response. Although there are not many reports about the severe immune reaction caused by Cas9, the antibodies of Cas9 have been widely identified in human bodies\[176\], which suggests the potential risk of inflammation during CRISPR/Cas9-based gene therapy. At present, researchers pay more attention to the immunogenicity caused by delivery vectors, especially the viral vectors, because the human body may have been infected by these viruses before and contain the corresponding antibodies already. Collectively, the immune reaction potentially induced by CRISPR/Cas9 gene-editing system is one of the major risk factors in the development of CRISPR-based gene therapy in vivo.

Multiple gene-editing

CRISPR/Cas9 is an efficient gene-editing tool but only edits one gene with a sgRNA simultaneously. Therefore, multiple gene-editing utilizing CRISPR/Cas9 have to rely on various sgRNAs, which decreases the editing efficiency while increases the delivery difficulty. Recent CRISPR/Cas12a may overcome the challenge, but other subsequent problems are still unsolved, including inactivation of cells and cell cycle arrest after multiple gene-editing. In the future, effective multiple gene-editing strategies will dramatically promote the gene therapy of polygenic diseases and cancers.

Outlook

CRISPR/Cas9, derived from the microbial innate immune system, is developed as a robust gene-editing tool and has been applied widely. Due to its high accuracy and efficiency, CRISPR/Cas9 techniques may provide a great chance to treat some gene-related diseases by disrupting, inserting, correcting, replacing, or blocking genes.

Cas9-mediated gene editing has been utilized to treat various non-cancerous diseases. Monogenetic diseases and X-linked diseases caused by gene mutation are the most direct and apparent kinds that CRISPR/Cas9 can be applied to. A number of studies have proved gene correction in monogenetic diseases and X-linked diseases is an effective therapeutic strategy, and several related clinical trials have been in the process recently. Similarly, the risk of CVDs is reduced, and the symptom of NDs is relieved dramatically after targeting related genes using CRISPR/Cas9. At the same time, the treatment of ocular diseases by Cas9 has entered into clinical phases. Noticeably, AIDS may become curable through knocking out the viral genes by Cas9, which benefits millions of patients in the world.

In terms of cancer therapy, CRISPR/Cas9 was initially applied in drug targets screen, causing a rapid discovery of lots of novel drug targets. Combined with computer and data techniques, Cas9-based target screening provides an advanced approach to understand cancers better. Disrupting oncogene or correcting tumor suppressor genes alone or in combination are the major strategy to treat cancers while knocking out viral genomes like HPV decreases the risk of virus-induced tumors. Moreover, some researches also demonstrate some regulator genes, epigenetic genes, and microenvironmental genes also play vital roles in cancerization and are developed as effective therapeutic targets. Recently, more researchers focus on the immune therapy of cancers. Especially CAR-T therapy has been applied in clinical treatment and achieves success to some extent, and the therapeutic effect may be improved by inhibiting some related genes by Cas9.

Admittedly, CRISPR/Cas9 is a robust gene-editing tool. However, some problems keep unsolved, including off-target effect, delivery challenges, Pam limitation, and immunogenicity, which blocks its application in clinical therapy. When developing gene therapy, the off-target effect and editing efficiency are two of the most concerning problems because the off-target effect may cause unexpected editing of normal genes and then lead to severe diseases or even death, while editing efficiency directly affects the therapeutic effect. To solve these two problems, lots of studies work in different aspects. Firstly, the delivery system of CRISPR/Cas9 is critical for CRISPR-based treatment. For example, the delivery efficiency determines the efficiency of Cas9-mediated gene editing to a considerable extent, and the targetability, stability, and release time of delivery vectors are highly related to the off-target effect. As mentioned above, disposable designs (such as delivering Cas9 protein) and all-in-one designs (such as delivering Cas9 plasmids and sgRNA simultaneously) are effective ways to decrease the off-target effect. Secondly, re-engineered or optimized Cas9 proteins reduce the off-target effect as well. Compared with traditional CRISPR/Cas9-based gene editing, base editing and primer editing tools do not create DSBs when editing genes, which dramatically

N. Guo, Ji-Bin Liu, W. Li et al. Journal of Advanced Research 40 (2022) 135–152
decreases the off-target effect. And their editing efficiency is continually enhanced in recent studies via optimizing enzymes or pegRNA, suggesting the great potential for clinical application. Finally, sgRNA design is still essential because it plays a key role in gene targeting. Except for optimizing sgRNA design rules and computer programs, the studies to avoid PAM limitation may improve the specification and flexibility of sgRNA, which is beneficial to improve editing efficiency while reducing the possibility of off-target. At present, most clinical trials just limit in editing genes in patient-derived cells ex vivo, and then the cells are injected back into the patient’s bodies, such as the treatment of SCDs and immune therapy (Fig. 6). This method avoids the risk of off-target effect and delivery challenge but is not suitable for all diseases. And recent research prefers to disrupt or knock out genes rather than correcting because the additional DNA templates increase the delivery difficulty. The clinical application of CRISPR/Cas9 is still at an early stage, and the prioritized problems of clinical gene therapy by Cas9 in vivo are off-target effect and delivery challenges.

Compared with monogenetic diseases, Cas9-based gene therapy of cancers are more challenging due to multiple gene mutations. Although it is available to exert multiple gene editing by CRISPR/Cas9 after adding the corresponding sgRNAs. CRISPR/Cas9-mediated multiple gene editing is not widely applied in clinical treatment or even gene function studies because it could lead to several potential problems, such as severe off-target effect and the deletion of big DNA fragments[177]. Therefore, novel approaches in multiple gene editing need to be developed further to overcome the present challenges.

Except for CRISPR/Cas9, other CRISPR systems, including Cas12a, Cas3 (with Cascade), Cas13, dCas9, and nCas9, also contain huge potentials for gene therapy[178]. For example, similar to Cas9, Cas12a also belongs to the class II CRISPR system. But Cas12a generates a staggered cut rather than the flat end that Cas9 creates, which is a great advantage when integrating DNA sequences. In the Cas3 system, the Cascade complex binds and recognizes the target DNA sequence then Cas3 proteins are recruited to generate a single-strand nick. Due to the promiscuous recognition of PAM in the Cas3 system, it is more flexible to target specific DNA sequences than Cas9. Different from Cas9, Cas12a, and Cas3 systems, Cas13 is an RNA-guided RNA targeting system. Cas13 could edit single-strand RNA efficiently, while nuclease-inactive dCas13 is able to regulate protein translation. Both dCas9 and nCas9 lose the nuclease activity but maintain the ability to target DNA sequences, so a lot of re-engineered CRISPR/Cas9 tools, such as CRISPRi, CRIPARa, base editing tool, and primer editing tools, etc., are based on dCas9 or nCas9.

In conclusion, CRISPR/Cas9 is an efficient gene-editing tool but not a perfect treatment approach at present. Lots of problems need to be developed further until its reliability and safety maintain a higher level. Cell therapy by Cas9 seems to be more simple to design while avoiding some troubles that in vivo gene therapy meets. However, only a few of hundreds of diseases could be treated by cell therapy. To provide a broader therapeutic strategy for genetic diseases, gene therapy by Cas9 is one of the major aspects to develop in the future. Therefore, how to efficiently and safely edit genes by CRISPR/Cas9 in vivo will be listed at the top in the next decade.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

---

**Fig. 6.** Clinical trail distribution. The recent CRISPR/Cas9-based clinical trails focus on the cancer and genetic hemolytic diseases treatment, accounting for 25 and 8 of 47 respectively, and 20 of 25 clinical projects adopts the immunotherapy for cancer treatment. China and US dominates the recent CRISPR/Cas9-based clinical trails, accounting for 20 and 16 of 47 respectively (from clinicaltrials.gov, accessed Jun-09-2021).
CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res. 2016;217:125–32.

Price AA, Sampson TR, Ratner HK, Grakoui A, Weiss DS. Cas9-mediated targeting of viral RNA in eukaryotic cells. Proc. Natl. Acad. Sci. 2015;112:1614–9.

Wang J, Quake SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesvirus infection. Proc. Natl. Acad. Sci. 2014;111:13157–62.

van Diemen FR et al. CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. PLOS Pathog. 2016;12:e1005701.

Yuen K-S et al. CRISPR/Cas9-mediated genome editing of Epstein-Barr virus in human cells. J. Gen. Virol. 2015;96:226–37.

Liang C et al. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 2017;147:68–85.

Liu T et al. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells. Cell. Physiol. Biochem. 2018;46:1218–36.

He Z-Y et al. In Vivo Ovarian Cancer Gene Therapy Using CRISPR/Cas9. Hum. Gene Ther. 2018;29:223–33.

Li X et al. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat. Cell Biol. 2020;22:282–8.

Singhal J et al. Targeting RLP with CRISPR/Cas9 controls tumor growth. Cancers (Basel) 2021;12:48–57.

Zhou L et al. Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer. Oncotarget 2018;9:9634–46.

Li J et al. Artificial Virus Delivers CRISPR/Cas9 System for Genome Editing of Cells in Mice. ACS Nano 2017;11:95–111.

Audrey BJ et al. An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo. Cell Rep. 2015;10:1422–32.

Chen Z-H et al. Targeting genome rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene. Nat. Biotechnol. 2017;35:543–90.

Delpi S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 2016;15:1985–99.

Ou X, Ma Q, Yin W, Ma X, He Z. CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. Front. Cell. Dev. Biol. 2021;9:1–12.

Schumman K et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. 2015;112:10437–42.

Su S et al. CRISPR/Cas9-mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci. Rep. 2016;6:20070.

Ren J et al. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. Clin. Cancer Res. 2017;23:2255–66.

Liu T et al. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. Oncotarget 2016;7:83502–13.

Mort R, Ray M, Lee YW, Scalleti F, Rotello VM. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges. Bioconjug. Chem. 2017;28:980–40.

Lino CA, Harper JC, Carney JP, Timlin JA. Delivering crispr: A review of the challenges and approaches. Drug Deliv. 2018;25:1234–57.

Hansen-Bruhn M et al. Active Intracellular Delivery of a Cas9/sgRNA Complex Using Ultrasound-Propelled Nanomotors. Angew. Chemie 2018;130:2687–91.

Hur J, Chung AJ. Microfluidic and Nanofluidic Intracellular Delivery. Adv. Sci. 2021;8.

Sessions JW et al. CRISPR-Cas9 directed knock-out of a constitutively expressed gene using lance array nanoinjection. Springerplus 2016;5:1521.

Yin H et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014;32:551–5.

Samulski R J & Muzykcz N. AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. doi:10.1146/annurev-virology-031413-085355.

Jiang, S. et al. CRISPR/Cas9-Mediated Genome Editing in Epstein-Barr Virus-Transformed Lymphoblastoid B-Cell Lines. Curr. Protoc. Mol. Biol. 2012; 31.12.1,31.12.23 (2018).

Park A et al. Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol. Ther. - Methods Clin. Dev. 2016;3:16057.

Mansouri M, Ehsaei Z, Taylor V, Berger P. Rbaculovirus-based genome editing in primary cells. Plasmid 2017;90:5–9.

Zuris JA et al. Catalytic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 2015;33:73–80.

Lao Y-H et al. HPV Oncogene Manipulation Using Nonviral Delivered CRISPR/Cas9 or Nanobacterium gregoryi Argonaute. Adv. Sci. 2018;5:1700540.

Zhang, L et al. Lipid nanoparticle-mediated efficient delivery of CRISPR/Cas9 for tumor therapy. NPG Asia Mater. 9, e441–e441 (2017).
Wen Li, Associate Professor, Ph.D., National Engineering Laboratory for Deep Process of Rice and Byproducts, College of Food Science and Engineering, Central South University of Forestry and Technology. He mainly engaged in research on functional components of food for cancer patients.

Ning Guo, M.S., National Engineering Laboratory for Deep Process of Rice and Byproducts, College of Food Science and Engineering, Central South University of Forestry and Technology. He mainly engaged in research on functional components of food for cancer patients.